Wednesday June 3, 2020

Elan reports "solid" start to 2012

UPDATE: Elan has reported a 17 per cent rise in revenues for the first quarter of the year and says opportunities in neurology are significant.

26th April, 2012
Elan's Kelly Martin

Elan has reported a 17 per cent rise in revenues for the first quarter of the year.

Revenues at the firm that focuses on neurological disorders totalled $288.4 million in the three months, Elan said.

Revenue from its multiple sclerosis drug Tysabri totalled $288.2 million, which was just ahead of expectations according to Bloomberg News.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 5 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago